Olive Oil Components as Novel Antioxidants in Neuroblastoma Treatment: Exploring the Therapeutic Potential of Oleuropein and Hydroxytyrosol

Marta Gonçalves,Anna Aiello,María Rodríguez-Pérez,Giulia Accardi,Emma Burgos-Ramos,Paula Silva
DOI: https://doi.org/10.3390/nu16060818
IF: 5.9
2024-03-14
Nutrients
Abstract:In this review, we explored the therapeutic potential of oleuropein (OLE) and hydroxytyrosol (HT) in the treatment of neuroblastoma (NB). NB is an extracranial tumour that predominantly affects children aged between 17 and 18 months. Recurrence and drug resistance have emerged as the biggest challenges when treating NB, leading to a crucial need for new therapeutic approaches. Food of the Mediterranean Diet (MD) presents several health benefits, including that of cancer treatment. In this review, we emphasised olive oil since it is one of the main liquid ingredients of the MD. OLE is the principal phenolic compound that constitutes olive oil and is hydrolysed to produce HT. Considering that tumour cells produce increased amounts of reactive oxygen species, this review highlights the antioxidant properties of OLE and HT and how they could result in increased cellular antioxidant defences and reduced oxidative damage in NB cells. Moreover, we highlight that these phenolic compounds lead to apoptosis and cell cycle arrest, reduce the side effects caused by conventional treatments, and activate tumours that become dormant as a resistance mechanism. Future research should explore the effects of these compounds and other antioxidants on the treatment of NB in vivo.
nutrition & dietetics
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the therapeutic potential of olive oil components as new antioxidants in the treatment of neuroblastoma (NB). Specifically, the paper focuses on the main phenolic compounds in olive oil - oleuropein (OLE) and hydroxytyrosol (HT), and discusses their potential roles in reducing oxidative stress, inducing cancer cell apoptosis and cell - cycle arrest, as well as how they may reduce the side effects of traditional treatment methods and activate tumor cells that have entered a dormant state due to drug resistance. Neuroblastoma is an extracranial tumor that mainly affects children aged 17 to 18 months. Recurrence and drug resistance are the greatest challenges in its treatment, so it is crucial to find new treatment methods. By reviewing existing research, the paper aims to evaluate the potential value of OLE and HT in the treatment of neuroblastoma and provide guidance for future research directions.